Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Full year trading statement

10 Jan 2025 07:00

RNS Number : 8294S
Anpario PLC
10 January 2025
 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

 

Anpario plc("Anpario", the "Group" or the "Company")

 

Full year trading statement

 

Anpario plc (AIM:ANP), the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, provides the following trading update for the year ended 31 December 2024 ("FY 2024"). The figures set out in this announcement remain subject to audit.

 

Trading update

The Group, including three months of trading for Bio-Vet Inc., delivered a stronger than expected operating performance in the second half of 2024. Year-end sales were higher than anticipated, and the Group now expects revenue for the 12 months ended 31 December 2024 to be approximately £37.5m* (31 December 2023: £31.0m). This strong performance in revenue combined with the Group's high operational gearing and favourable year-end foreign exchange movements, will result in adjusted EBITDA being ahead of current market expectations*.

 

Bio-Vet Inc. had a strong final quarter due to heightened demand for its products, which support the health of dairy cows affected by avian influenza, and our Middle East and Africa segment delivered an outstanding sales performance.

 

Financial position

Our financial position remains strong, with year-end cash balances of £10.5m* (31 December 2023: £10.6m), after accounting for the acquisition of Bio-Vet Inc. and associated land and buildings for an initial cash consideration of US$6.3m, on a debt-free basis, which completed in September 2024.

 

Our strong balance sheet enables the Group to invest in innovative natural product solutions, expand our global reach and explore earnings enhancing and complementary acquisitions to continue the profitable development of the Group. We remain confident in our ability to capitalise on growth opportunities, delivering long-term benefits to all stakeholders.

 

FY2024 Results

The Group expects to publish its FY 2024 final results on or around 26 March 2025.

 

 

 

*Analyst consensus for FY 2024 immediately prior to this announcement was Revenue of £35.25m, EBITDA of £5.7m and net cash of £7.2m.

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUUUGUPAPWB
Date   Source Headline
12th Jul 20171:43 pmRNSDirector/PDMR shareholding and Total Voting Rights
30th Jun 20177:00 amRNSDirector/PDMR Shareholding
29th Jun 201712:06 pmRNSResult of AGM
29th Jun 20177:00 amRNSAGM Statement
19th Jun 20172:15 pmRNSHolding(s) in Company
7th Jun 20174:22 pmRNSHolding(s) in Company
5th Jun 201710:20 amRNSDividend date
26th May 20171:53 pmRNSNotice of AGM
23rd May 20173:31 pmRNSHolding(s) in Company
9th May 20175:21 pmRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSDirector Declaration
10th Mar 20177:00 amRNSDirector/PDMR Shareholding
8th Mar 20177:00 amBUSFinal Results
1st Mar 20178:39 amRNSHolding(s) in Company
23rd Feb 20177:00 amRNSReplacement Announcement
15th Feb 20174:29 pmRNSHolding(s) in Company
15th Feb 20172:35 pmRNSBLOCK LISTING SIX MONTHLY RETURN
3rd Feb 20177:00 amRNSAcquisition
2nd Feb 20177:00 amRNSTrading Statement
1st Dec 20167:00 amRNSTotal Voting Rights
22nd Nov 20167:00 amRNSEmployee Share Plan and Directors' Dealing
6th Oct 201611:46 amRNSHolding(s) in Company
16th Sep 20164:36 pmRNSDirector/PDMR Shareholding and Share Plan Limits
14th Sep 20167:30 amBUSHalf-year Report
9th Sep 20163:21 pmRNSTotal Voting Rights
4th Aug 20163:33 pmRNSTotal Voting Rights
4th Aug 20163:32 pmRNSBlock listing Interim Review
6th Jul 20165:00 pmRNSDirector/PDMR Shareholding
6th Jul 20167:00 amRNSHolding(s) in Company
4th Jul 20163:38 pmRNSTotal Voting Rights
29th Jun 20165:17 pmRNSResult of AGM
28th Jun 20167:00 amRNSAGM Statement
13th Jun 20167:00 amRNSTotal Voting Rights
21st Apr 201612:05 pmRNSHolding(s) in Company
8th Mar 20167:00 amBUSFinal Results
29th Feb 20164:59 pmRNSBlocklisting Interim Review
1st Feb 20167:00 amRNSTrading Statement
13th Jan 201611:00 amRNSBoard and Management Changes
3rd Dec 201511:19 amRNSHolding(s) in Company
1st Dec 20157:00 amRNSTotal Voting Rights
21st Sep 20155:23 pmRNSDirector/PDMR Shareholding
16th Sep 20154:55 pmRNSDirector/PDMR Shareholding
16th Sep 20157:00 amBUSHalf-yearly Report
31st Jul 20153:40 pmRNSTotal Voting Rights
31st Jul 20153:39 pmRNSBlocklisting Interim Review
25th Jun 20151:21 pmRNSResult of AGM
25th Jun 20157:00 amRNSAGM Statement
2nd Jun 20152:49 pmRNSHolding(s) in Company
27th May 20158:38 amRNSDirector/PDMR Shareholding
22nd Apr 20151:52 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.